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Our study confronts the use of antimicrobial agents in 
ambulatory care with the resistance trends of 2 major patho-
gens, Streptococcus pneumoniae and Escherichia coli, in 
21 European countries in 2000–2005 and explores whether 
the notion that antimicrobial drug use determines resistance 
can be supported by surveillance data at national aggre-
gation levels. The data obtained from the European Sur-
veillance of Antimicrobial Consumption and the European 
Antimicrobial Resistance Surveillance System suggest that 
variation of consumption coincides with the occurrence of 
resistance at the country level. Linear regression analysis 
showed that the association between antimicrobial drug use 
and resistance was speciﬁ  c and robust for 2 of 3 compound 
pathogen combinations, stable over time, but not sensitive 
enough to explain all of the observed variations. Ecologic 
studies based on routine surveillance data indicate a rela-
tion between use and resistance and support interventions 
designed to reduce antimicrobial drug consumption at a na-
tional level in Europe.
F
or the past 60 years, antimicrobial chemotherapy has 
been the mainstay of medical intervention against 
infectious diseases caused by bacterial pathogens. The 
continuous decline of therapeutic effectiveness as a re-
sult of extensive use of antimicrobial chemotherapy has 
been long predicted and seems inescapable (1). Many 
surveillance efforts have over the last decade (1997–
2007) drawn attention to this phenomenon (2–5). At 
the same time, the once-abundant supply of new and 
improved antimicrobial compounds has worn thin, as 
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drug development becomes increasingly challenging 
and pharmaceutical companies invest in more lucrative 
markets (6). It is therefore critical to realize that antimi-
crobial drug effectiveness, widely accepted as a com-
mon good, cannot be taken for granted and that such 
substances are increasingly attaining the status of non-
renewable resources.
Our study confronts the population-adjusted use of 
antimicrobial agents in ambulatory care with the resis-
tance trends of 3 compound pathogen combinations in 
21 European countries over a period of 6 years (2000–
2005). This initial study was made possible by combining 
data from the 2 most comprehensive European surveil-
lance systems on antimicrobial drug consumption and 
resistance, the European Surveillance of Antimicrobial 
Consumption (ESAC) (7) and the European Antimicro-
bial Resistance Surveillance System (EARSS) (8). We 
present an authoritative joint analysis of these 2 compre-
hensive databases. At this highly aggregated level, data 
are not sensitive enough to unravel the complex interac-
tion between prescribing and resistance. The goal of this 
study is to give an overview of the situation in the Euro-
pean region and explore whether a relationship between 
antimicrobial drug use and resistance can be supported 
by empirical data pooled at national levels.
Materials and Methods
Consumption of Antimicrobial Agents
ESAC collects data on antimicrobial drug use in 
ambulatory care and hospital care in Europe. Current-
ly, 24 countries report data on ambulatory care con-
sumption to ESAC (9). Prescribed drugs are grouped 
by the active substance as the number of deﬁ  ned daily 
doses (DDD) per 1,000 inhabitants (DID) according to 
the World Health Organization deﬁ  nition of Anatomi-
cal Therapeutic Chemical Classiﬁ  cation (ATC) deﬁ  ned 
daily dose (ATC-DDD version 2005 (10). A complete 
description of the data providers and details of the 
methods used by ESAC have been published (7,11,12). 
The performance and methodologic approach of the 
ESAC system, which aimed to collect comparable and 
reliable data on antimicrobial drug use, were studied 
by Vander Stichele et al. (7). The collected data were 
screened for bias caused by errors in assigning medici-
nal product packages to the ATC; errors in calculations 
of DDD per package; bias by over-the-counter sales 
and parallel trade; and bias in ambulatory care/hospital 
care mix. The study indicated that of the 31 participat-
ing countries, 21 delivered ambulatory care data suit-
able for cross-national comparison (7).
For the present study, the total country-speciﬁ  c anti-
microbial drug use in ambulatory care and a breakdown 
into the following major antimicrobial classes were 
extracted from the ESAC database: penicillins (J01C); 
other  β-lactam antimicrobial agents (cephalosporins, 
monobactams and carbapenems, J01D); macrolides, lin-
cosamines, and streptogramins (MLS-class, J01F); and 
ﬂ  uoroquinolones (J01MA).
Resistance to Antimicrobial Agents
EARSS performs continuous surveillance of antimi-
crobial drug susceptibility for 7 major bacterial patho-
gens that cause invasive infections. Data are provided 
by >900 microbiologic laboratories that serve ≈1,400 
hospitals from 32 countries with an overall hospital 
catchment population estimated to include >100 million 
inhabitants (13). All EARSS participating laboratories 
perform routine antimicrobial drug susceptibility tests 
according to standard protocols (14) and interpret their 
susceptibility results according to harmonized national 
and international guidelines as sensitive, intermediately 
resistant, and resistant (15). More details about the data 
acquisition and analysis have been published elsewhere 
(13,16,17). The antimicrobial susceptibility test (AST) 
results reported by the laboratories are collected by us-
ing standardized protocols as described in the EARSS 
manual (www.rivm.nl/earss). Data that do not meet the 
requirements of these species-speciﬁ  c protocols are not 
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accepted. To assess the comparability of results between 
laboratories participating in EARSS, an external qual-
ity assessment exercise is organized every year. A set 
of 6 strains is provided to each laboratory in collabora-
tion with the UK National External Quality Assurance 
Scheme. These exercises illustrate that routinely report-
ed results, as collected by EARSS, have sufﬁ  cient ac-
curacy to provide good estimates of overall resistance 
prevalences and trends (18).
For the present study, AST results of primary blood 
culture isolates of Escherichia coli and Streptococcus 
pneumoniae were extracted from the EARSS database 
to determine the proportions of penicillin- and erythro-
mycin-nonsusceptible S. pneumoniae (PNSP and ENSP, 
respectively) and proportions of ﬂ  uoroquinolone-resis-
tant E. coli (FQRE) bacteria. Nonsusceptible isolates 
included both intermediate resistant and resistant iso-
lates. A country-speciﬁ  c resistance score was calculated 
as the sum of the quartile ranks of resistance against all 
3 compound pathogen combinations (PNSP, ENSP, and 
FQRE). For trend analysis of resistance proportions per 
country over time, the Cochrane-Armitage trend test 
was used.
Ecologic Analysis
The strength of association between antimicrobial 
drug use and resistance was determined by univariate and 
multiple linear regression analysis. The proportion of re-
sistance (R) in a country was transformed to the natural 
logarithm of the odds of resistance (ln[R/1–R]), to get a 
range from –∞ to +∞. The log odds of resistance (as the 
dependent variable) can then be expressed as a simple 
linear function of the independent variable (consump-
tion) (19,20). To give equal weight to small countries 
with ﬂ  awless data collection and not give the unequal 
weight to larger countries with sometimes less-optimal 
data, the linear regression analysis was not weighed.
To determine the delay between antimicrobial use 
and resistance, proportions of PNSP, ENSP, and FQRE 
for 2002–2005 were correlated with the consumption 
of different antimicrobial drug classes in the same year 
and the 2 years before. This resulted in 11 different ex-
posure-outcome intervals for each compound–pathogen 
combination. For further multivariate analysis, the inter-
val with the median correlation coefﬁ  cient was regarded 
as representative for the association found in the overall 
study period.
Only the countries that reported volumes of antimi-
crobial drug prescriptions in ambulatory care from 2000 
through 2004 and susceptibility data for the selected 
compound–pathogen combinations from 2002 through 
2005 were included for linear regression analysis. Coun-
tries that provided yearly susceptibility data for <20 iso-
lates were excluded. Data analysis was conducted by us-
ing SAS version 9.1 software (SAS Institute Inc., Cary, 
NC, USA).
Results
Consumption of Antimicrobial Agents
We included in the study 21 European countries, 
which provided data on the use of antimicrobial agents 
in ambulatory care to the ESAC database for the period 
2000–2004 (including the 15 long-standing European 
Union (EU) member states). These also included 3 of the 
10 nations that joined the EU in May 2004, the Czech 
Republic, Slovakia, and Slovenia; 2 applicant countries, 
Bulgaria and Croatia; and 1 European Free Trade Asso-
ciation country, Iceland. Total outpatient antimicrobial 
drug use differed signiﬁ  cantly between countries. Use 
tends to be low in northern, moderate in central, and 
high in southern Europe and varied by a factor of 3.4 be-
tween Greece (33.4 DID) and the Netherlands (9.7 DID) 
in 2004 (Figure 1, Table 1). 
During the observation period (2000–2004), antimi-
crobial drug use decreased (>15%) in Bulgaria, Czech 
Republic, France, and Germany and increased (>15%) 
in Croatia, Denmark, Greece, and Ireland. Penicillins 
(including broad-spectrum penicillins, ATC category 
J01C) represented the most widely used antimicrobial 
class in Europe. This class showed consumption pat-
terns similar to the total outpatient antimicrobial drug 
use, as did the second most widely used category, 
which consists mainly of macrolides but also includes 
lincosamines and streptogramins (MLS class, ATC cat-
egory J01F). The third most widely used ATC catego-
ry (J01D, other β-lactams) consists of cephalosporins, 
monobactams, and carbapenems. Cephalosporins make 
up the bulk of the antimicrobial agents included in this 
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Figure 1. Total antimicrobial drug consumption in ambulatory care 
in deﬁ   ned daily doses per 1,000 inhabitants per day (DID) by 
antimicrobial class in 21 European countries in 2004. See Table 1 
footnote for country designations.Antimicrobial Drug Use and Resistance in Europe
group. Antimicrobial agents belonging to this category 
are more commonly used in hospitals; however, in some 
countries they are also extensively prescribed in ambu-
latory care. For this reason, use rates in Europe varied 
>100-fold between countries. The use of this ATC cat-
egory decreased by >15% in 8 countries but increased 
in Slovenia. Fluoroquinolones hold the fourth position 
in the European market but showed the most dynamic 
increase, with growth rates of >15% in almost half of 
all countries (10/21). In terms of overall control of an-
timicrobial drug consumption, France most consistently 
reduced its use of 3 of the 4 most frequently prescribed 
antimicrobial drug classes (Figure 1, Table 1).
Resistance to Antimicrobial Agents
Large differences in the proportions of resistance 
were reported for the same countries. The highest an-
timicrobial drug resistance was found in Spain, Hun-
gary, and France and the lowest in Sweden and the 
Netherlands in 2005 (Figure 2). Resistance proportions 
in 2005 differed by a factor of 27.7 for PNSP between 
France (36%) and the Netherlands (1.3%), by 20.5 
for ENSP between France (41%) and the Czech Re-
public (2%), and by 9.7 for ﬂ  uoroquinolone resistance 
in E. coli between Portugal (29%) and Iceland (3%). 
From 2001 through 2005, resistance levels remained 
relatively stable for PNSP but increased for the other 
2 compound pathogen combinations (Table 2). Spain 
and the United Kingdom were the only countries that 
reported any signiﬁ  cant decrease in antimicrobial drug 
resistance rates. In Spain, penicillin nonsusceptibility 
fell from 37% to 25% and in the United Kingdom, from 
5% to 3.8%. For ENSP a signiﬁ  cant increase was ob-
served in Hungary (from 19% to 37%), Finland (from 
12% to 20%), and the Netherlands (5% to 11%). The 
most consistent trend was observed for ﬂ  uoroquinolone 
resistance in E. coli, which increased in most European 
countries (Table 2).
Combining Antimicrobial Drug Use 
with Susceptibility Data
Greece (33.0 DID), France (27.1 DID), Luxem-
bourg (24.2 DID), Portugal (23.8 DID), Croatia (23.0 
DID), and Belgium (22.9 DID) were the countries that 
reported the highest use of antimicrobial agents in am-
bulatory care. Four of these high-consumer countries—
France, Luxemburg, Belgium, and Portugal—were also 
among the 6 countries with the highest resistance pro-
portions. Croatia occupied an intermediate resistance 
rank, owing to more modest levels in ﬂ  uoroquinolone 
resistance. For Greece, susceptibility data for S. pneu-
moniae were not available, which precluded a meaning-
ful ranking. Although Spain (18.7 DID) and Hungary 
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Table 1. Difference in outpatient antimicrobial drug use DID in 21 European countries, 2004, and changes in use, 2000–2004*† 
Antimicrobial use, DIDs, 2004  Changes in antimicrobial drug use, 2000–2004 
Substance class (ATC category) 
Maximum 
(country) 
Minimum
(country)  fd >15% increase  >15% decrease 
Total use (J01) 33.4 (GR) 9.7 (NL) 3.4 HR, DK, GR, IE  BG, CZ, DE, FR
Penicillins (J01C) 12.8 (FR) 3.4 (DE) 3.8 HU, DK CZ, FR, DE, SK
Cephalosporins, monobactams, 
carbapenems (J01D)
7.2 (GR) 0.05 (NL) >100 SI BE, BG, CZ, FR, IS NL, 
ES, SE 
Macrolides, lincosamines, 
streptogramins (J01F)
9.9 (GR) 0.8 (BG) 12.4 BG, HR, GR, IE, NL BE, FR, DE, LU, ES
Fluoroquinolones (J01MA) 3.04 (PT) 0.28 (DK) 10.9 AT, BG, CZ, DK, FI, 
DE, HU, IE, LU, UK
SI
*DID, defined daily dose/1,000 inhabitants; ATC, Anatomic Therapeutic Chemical classification; fd, factor difference. 
†Country designations: AT, Austria; BE, Belgium; BG, Bulgaria; CZ, Czech Republic; DE, Germany; DK, Denmark; ES, Spain; FI, Finland; FR, France; 
GR, Greece; HR, Croatia; HU, Hungary; IE, Ireland; LU, Luxembourg; NL, the Netherlands; PT, Portugal; SE, Sweden; SI, Slovenia; SK, Slovakia; UK, 
United Kingdom. 
Figure 2. Proportion of penicillin-nonsusceptible Streptococcus 
pneumoniae (PNSP), erythromycin-nonsusceptible S. pneumoniae 
(ENSP), and ﬂ  uoroquinolone-resistant Escherichia coli (FQRE) in 
2005, ranked in descending order by country-speciﬁ  c resistance 
score indicated above bars. *For Greece and Slovakia, data on S. 
pneumoniae resistance were not available. Country (total no. of S. 
pneumoniae isolates reported/ total no. of E. coli isolates reported): 
ES (740/2993); HU (86/468); FR (632/6028); LU (43/188); PT 
(202/1086); BE (1539/1461); BG (43/196); DE (119/957); HR 
(129/637); IE (397/1411); AT (290/2049); FI (525/1743); SI (208/657); 
CZ (194/2233); UK (1373/2359); IS (37/117); DK (1081/1283); NL 
(802/2140); SE (1017/3035); GR (0/1136); SK (0/132). See Table 1 
footnote for country designations.
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(18.6 DID) were not among the countries with the high-
est use of antimicrobial agents, both countries did have 
the highest antimicrobial drug resistance proportions in 
2005. The United Kingdom (15.2 DID), Sweden (15 
DID), Denmark (14.1 DID), Austria (12.5 DID), Ger-
many (11 DID), and the Netherlands (10 DID) reported 
the lowest antimicrobial drug use in outpatient settings. 
Of these, Sweden, the Netherlands, Denmark, and the 
United Kingdom also were among the 6 countries with 
the lowest resistance proportions. Germany and Aus-
tria reported medium to high rates especially for ENSP 
(17% and 15%, respectively) and FQRE (23% and 19%, 
respectively) (Figures 1, 2). Because inspection of the 
data suggested a relation between antimicrobial drug 
consumption and resistance, this assumption was for-
mally tested by using simple linear regression.
Because little is known about the delay that can 
be expected between the change in antimicrobial drug 
exposure and its effect on antimicrobial resistance at 
a population level, different intervals were chosen to 
explore the potential association between use and re-
sistance. Intervals were explored for same-year data, a 
1-year delay, and a 2-year delay between exposure and 
outcome. Thus, the consumption data available for 2000 
through 2004 and resistance data for 2002–2005 provid-
ed the means to explore the correlation coefﬁ  cients of 11 
exposure-outcome intervals. Only the 17 countries that 
provided data for all years were included in the linear 
regression analysis. Table 3 shows the range and median 
correlation coefﬁ  cient for all exposure-outcome inter-
vals. Since no statistically signiﬁ  cant time dependence 
was observed, the median correlation coefﬁ  cient was re-
garded as representative for the association found for the 
entire study period (Table 3).
The occurrence of PNSP in European countries 
correlated with the country-speciﬁ  c use of penicillins, 
which explained 61% of the observed variance (p<0.01) 
(Figure 3). The second best correlation was provided 
by the total antimicrobial drug use in ambulatory care, 
which explained 46% of the observed variance (p<0.01). 
Both associations were robust and remained signiﬁ  cant, 
regardless of the interval between the ascertainment of 
antimicrobial drug use and the recording of antimicro-
bial resistance. A notably less consistent association 
was found when we correlated the use of MLS-class 
antimicrobial agents or ﬂ  uoroquinolones with the occur-
rence of PNSP (Table 3). ENSP occurrence in Europe 
correlated most compellingly with the country-speciﬁ  c 
use rate of ATC category J01D (other β-lactams), which 
explained 48% of the observed variance (p<0.01) (Table 
3). However, this effect appeared to be confounded by 
the use of MLS-class antimicrobial agents and ﬂ  uoro-
quinolones. By ﬁ  tting use data for these antimicrobial 
agents into the model, the effect estimates for the former 
decreased by 40% (Table 4), indicating that part of the 
effect attributed to the use of other β-lactam antimicro-
bial agents appeared to be exerted by MLS-class antimi-
crobial agents and ﬂ  uoroquinolones.
Proportions of FQRE in European countries were 
best explained by the country-speciﬁ  c use data for ﬂ  uo-
roquinolones. Fluoroquinolone consumption as reported 
to the ESAC network explained 36% of the variance 
observed in EARSS data (p<0.01; Figure 4). This ef-
fect appeared to be speciﬁ  c and was not associated or 
confounded by consumption of the other antimicrobial 
classes.
Discussion
We compared the trends in antimicrobial drug con-
sumption patterns and the antimicrobial drug resistance 
proportions for 2 major pathogens, S. pneumoniae and E. 
coli, in Europe from 2000 through 2005. Antimicrobial 
drug use in outpatient settings was ascertained by the 
most comprehensive network for European surveillance 
of antimicrobial consumption (ESAC), and antimicrobi-
al resistance data were obtained from the European sur-
veillance system (EARSS). The data suggested that in 
Europe the variation of consumption coincides with the 
occurrence of resistance at country level. Using simple 
linear regression analysis, we formally explored whether 
a relation between country-speciﬁ  c antimicrobial drug 
use and antimicrobial resistance can be inferred at na-
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Table 2. Differences in the proportion of antimicrobial drug resistance in 21 European countries, 2005, and significant trends, 2001–
2005
Antimicrobial drug resistance
Europe, %, 2005 Trends, 2001–2005* Compound-
pathogen† Maximum (country) Minimum (country) fd‡ Increase (p<0.05) Decrease (p<0.05)
PNSP 36 (FR) 1.3 (NL) 27.7 BG ES, UK
ENSP 41 (FR) 2 (CZ) 20.5 FI, HU, NL 
FQRE 29 (PT) 3 (IS) 9.7 AT, BE, BG, CZ, DE, ES, FI, HR, 
HU, LU, NL, PT, SE
*No trend analysis was performed for Denmark and France, and for Ireland and the United Kingdom for proportion of Escherichia coli resistant to 
fluoroquinolones (FQRE), because data were not available for all years of the study period (2001–2005). See Table 1 footnote for country designations. 
†PNSP, proportion of Streptococcus pneumoniae not susceptible to penicillin; ENSP, erythromycin-nonsusceptible S. pneumoniae.
‡fd, factor difference. Antimicrobial Drug Use and Resistance in Europe
tional aggregation levels and found that the association 
between antimicrobial drug use and resistance was spe-
ciﬁ  c and robust for 2 of the 3 compound pathogen com-
binations under study, stable over time, but not sensitive 
enough to explain all of the observed variation.
There was a high degree of consistency between 
penicillin use and penicillin nonsusceptibility in pneu-
mococci as well as for ﬂ  uoroquinolone use and an in-
crease in ﬂ  uoroquinolone resistance in E. coli. Simple 
linear regression showed that these effects were highly 
speciﬁ  c and robust, as inclusion of the use of other 
antimicrobial substances did not improve correlation 
or was not confounding the overall effect estimates 
(Tables 3, 4; Figures 3, 4). The mechanisms for acquir-
ing resistance against both substances have some fea-
tures in common. These include successive alterations 
of chromosomally located genes by either homologous 
recombination or point mutations, resulting in a step-
wise modiﬁ  cation of the molecular targets, which ﬁ  rst 
leads to reduced susceptibility and eventually to com-
plete resistance (21,22). In contrast to many other re-
sistance mechanisms, no mobile genetic elements are 
involved, and a physical linkage to other resistance 
determinants is unlikely. It is therefore expected that 
before phenotypes with stable combined resistance 
evolve, antimicrobial drug selection will speciﬁ  cally 
favor homologous resistance.
A nonhomologous effect was observed in the case 
of ENSP, since the variance in ENSP occurrence was 
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Table 3. Range and median correlation between the occurrence (logodds) of PNSP, ENSP, and FQRE in 2002–2005 and antimicrobial 
drug consumption, Europe, 2000–2004* 
Correlation coefficients (r)
Median Minimum Maximum 
E consumption 
O-
resistance
phenotype 
No. E–O 
intervals with 
significant
association† r (CI) 
E–O 
year r (CI) 
E–O 
year r (CI) 
E–O 
year
PNSP 11 0.68
(0.30–0.87)
2003–
2003
0.61
(0.17–0.84)
2001–
2003
0.73
(0.39–0.90)
2002–
2002
Total use (J01)
ENSP 9 0.55
(0.07–0.82)
2001–
2003
0.37
(–0.11 to 0.75)
2004–
2005
0.71
(0.33–0.89)
2003–
2003
PNSP 11 0.78
(0.48–0.92)
2003–
2004
0.69
(0.28–0.87)
2003–
2005
0.82
(0.55–0.93)
2004–
2004
Penicillins (J01C) 
ENSP 3 0.37
(–0.15 to 0.74)
2003–
2005
0.26
(–0.29 to 0.66)
2001–
2002
0.60
(0.15–0.84)
2003–
2003
PNSP 8 0.57
(0.13–0.83)
2002–
2003
0.41
(–0.07 to 0.74)
2002–
2004
0.64
(0.23–0.86)
2000–
2002
Cephalosporins,
monobactams,
carbapenems
(J01D)
ENSP 11 0.69
(0.30–0.88)
2001–
2002
0.50
(0.00–0.79)
2003–
2005
0.79
(0.48–0.92)
2004–
2004
PNSP 4 0.42
(–0.08 to 0.75)
2004–
2004
0.26
(–0.22 to 0.67)
2004–
2005
0.53
(0.07–0.81)
2002–
2002
Macrolides,
lincosamides,
streptogramins
(MLS class J01F)
ENSP 9 0.56
(0.08–0.82)
2001–
2002
0.35
(–0.19 to 0.71)
2004–
2004
0.67
(0.27–0.88)
2003–
2004
PNSP 9 0.51
(0.04–0.80)
2004–
2004
0.36
(–0.10 to 0.74)
2003–
2005
0.57
(0.12–0.82)
2002–
2002
ENSP 10 0.62
(0.18–0.85)
2001–
2002
0.48
(–0.04 to 0.78)
2004–
2005
0.69
(0.29–0.89)
2004–
2004
Fluoroquinolones 
(JO1MA)
FQRE‡ 9 0.60
(0.17–0.84)
2004–
2004
0.44
(–0.05 to 0.76)
2003–
2005
0.70
(0.33–0.88)
2001–
2002
*PNSP, penicillin-nonsusceptible Streptococcus pneumoniae; ENSP, erythromycin-nonsusceptible S. pneumoniae; FQRE, fluoroquinolone-resistant 
Escherichia coli; E, exposure; O, outcome; CI, 95% confidence interval; MLS, macrolides, lincosamines, and streptogramins.  
†Exposure outcome intervals include all 11 possible time windows, considering the data for consumption (exposure) and resistance (outcome) for the 
same year as well as for intervals of 1 to 2 y between exposure and outcome. p<0.05 was significant. 
‡Significant correlations of fluoroquinolone consumption were found only with FQRE. Other correlations were therefore not shown.
Figure 3. Occurrence of penicillin-nonsusceptible Streptococcus 
pneumoniae (PNSP) plotted against outpatient use of penicillins 
in 17 European countries including 95% conﬁ  dence intervals. DID, 
deﬁ  ned daily doses per 1,000 inhabitants. See Table 1 footnote for 
country designations.RESEARCH
best explained by the country-speciﬁ  c use rates of the 
ATC category of other β-lactams, consisting mainly of 
cephalosporins. This observation could be either causal, 
coincidental, or both. In fact, the results of multiple re-
gression models indicate a degree of confounding, as 
part of the effect attributed to other β-lactams could be 
explained by MLS-class antimicrobial agents and ﬂ  uo-
roquinolones (Table 4). This confounding effect implies 
that the effect of other β-lactams is mixed with the ef-
fect of MLS-class antimicrobial agents and ﬂ  uoroquino-
lones used. Data recorded by ESAC suggest that most 
countries with high use of other β-lactams also have a 
high consumption of MLS-class antimicrobial agents 
(r = 0.78, p<0.01) as well as ﬂ  uoroquinolones (r = 0.65, 
p<0.01). Moreover, countries with the highest levels of 
other β-lactam use—such as Luxembourg, Croatia, Por-
tugal, Belgium, and France—and high levels of ENSP 
(23%, 19%, 20%, 31%, and 41%) also reported high 
levels of combined nonsusceptibility to both erythro-
mycin and penicillin (12%, 9%, 10%, 9%, and 32%). 
Any increase in selection pressure exerted by β-lactams 
would also co-select for ENSP under these conditions 
of combined nonsusceptibility, which could also explain 
the absence of a direct relationship between use of MLS-
class antimicrobial agents and ENSP.
For all compound pathogen combinations that 
showed signiﬁ  cant correlations, the association between 
the volume of antimicrobial agents used and proportions 
of resistance was for the most part stable, i.e., indepen-
dent of the time lag between recording of consumption 
and the recording of resistance (Table 3). This is not sur-
prising because in the absence of nationwide interven-
tions that would abruptly change the use pattern for an 
entire country, no major trend changes would be expect-
ed, or as other authors have already stated, it is likely that 
a country with more use or resistance than others in one 
year, will also have more use or resistance in the next 
(19). Likewise, the steady decline in the consumption in 
some of the antimicrobial drug classes such as penicil-
lins, as happened in the Czech Republic, France, Ger-
many, and Slovakia, was not reﬂ  ected by a concomitant 
decline of penicillin resistance in the pathogens under 
selective pressure. Mathematical models as well as em-
pirical data suggest that after a reduction in prescribing, 
resistance will take longer to decline than it took to rise 
(23). In the same way, no decline in resistance against 
co-trimoxazole was observed in the United Kingdom 
even 10 years after it abandoned its prescribing, which 
in this instance was attributed to the co-selection of ge-
netically linked resistance determinants by alternative 
antimicrobial pressure (24). EARSS data show a signiﬁ  -
cant reduction of penicillin resistance in Spain (25) and 
the United Kingdom over the past 5 years (2001–2005), 
however, no corresponding decline in penicillin use has 
become apparent that could explain this favorable de-
velopment (Tables 1, 2). Alternatively, data aggregated 
at country level by established surveillance networks 
may not be sensitive enough to identify subtle changes 
in the complex interaction between antimicrobial drug 
prescribing and resistance.
EARSS data consist of antimicrobial drug resistance 
proportions of bacteria that cause invasive bloodstream 
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Figure 4. Occurrence of ﬂ  uoroquinolone-resistant  Escherichia 
coli (FQRE) plotted against outpatient use of ﬂ  uoroquinolone 
antimicrobial agents in 17 European countries including 95% 
conﬁ  dence intervals. DID, deﬁ  ned daily doses/1,000 inhabitants. 
See Table 1 footnote for country designations.
Table 4. Results of multiple linear regression for the occurrence 
of PNSP and ENSP* 
Outcome variable: logodds PNSP 
Models  Exposure 
Parameter 
estimate  p value R
2 
Model 1         
 Intercept    –4.75    
 Gradient  Penicillins  0.29  0.0002  0.61 
Model 2        
 Intercept    –4.8    
Penicillins  0.33  0.002   
Other ȕ-lactams  –0.05  0.808   
 Gradient 
Fluoroquinolones  –0.11  0.73  0.62 
  Outcome variable: logodds ENSP 
Model 1         
 Intercept    –2.82    
 Gradient  Other  ȕ-lactams  0.41  0.003  0.48 
Model 2        
 Intercept    –3.26    
Other ȕ-lactams  0.25  0.14   
MLS class  0.15  0.39   
 Gradient 
Fluoroquinolones  0.30  0.35  0.56 
*PNSP, penicillin-nonsusceptible Streptococcus pneumoniae; ENSP, 
erythromycin-nonsusceptible S. pneumoniae; MLS, macrolides, 
lincosamines, and streptogramins. Antimicrobial Drug Use and Resistance in Europe
infections but do not include information from other po-
tentially relevant patient materials. This omission limits 
the wealth of data but improves the comparability be-
tween participating laboratories because it reduces bias 
introduced by differential case ascertainment. S. pneu-
moniae is the main cause of community-acquired bacter-
emic pneumonia (26), and invasive E. coli infections are 
mainly caused by the translocation of intestinal coloniz-
ing strains (27). Thus, we believe that resistance among 
S. pneumoniae and E. coli blood culture isolates would 
sufﬁ  ciently reﬂ  ect the ecological pressure exerted by the 
antimicrobial drug use in outpatient settings.
There is little doubt that antimicrobial drug con-
sumption is important in the dissemination of antimicro-
bial drug resistance. However, additional or alternative 
factors need to be taken into account (28). 
We could not control for country-speciﬁ  c differ-
ences in hygiene, diagnostic habits, community infec-
tion control, and vaccination policies that could provide 
alternative explanations for some of the observed dif-
ferences. Moreover, inconsistencies in the sampling 
population covered by the 2 surveillance systems may 
introduce inaccuracies that hamper the internal valid-
ity of this type of analysis (29). In general, data at this 
high aggregation level are probably not sensitive enough 
to reﬂ  ect subtle changes in the complex interaction be-
tween antimicrobial drug prescribing and resistance. In 
this respect, increasing the geographic resolution of data 
collection by addressing antimicrobial drug use and re-
sistance at the level of health districts would improve 
the analysis and degree of causal inference that these 
studies could provide. A higher geographic resolution 
could also foster interventions by making local extremes 
of use apparent. However, despite these drawbacks, the 
data suggest that a speciﬁ  c, robust, and stable associa-
tion exists between antimicrobial drug use and the oc-
currence of resistance at country level in the European 
Union. Our results therefore support interventions that 
encourage healthcare professionals and healthcare au-
thorities to take ﬁ  rm steps toward promoting prudent use 
and careful restriction of antimicrobial drug prescription 
and to monitor the effect of these interventions toward 
the restoration of the antiinfective activity essential to 
the success of modern medicine.
EARSS and ESAC are funded by the European Commission. 
EARSS is coﬁ  nanced by the Dutch Ministry of Health, Welfare 
and Sports, the Netherlands.
Dr van de Sande-Bruinsma has been part of the EARSS man-
agement team since 2001. Her research interest is antimicrobial 
drug resistance.
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